Obewist 10 Tablet contains Obeticholic acid 10 mg, a potent farnesoid X receptor (FXR) agonist used primarily in the treatment of chronic liver diseases such as primary biliary cholangitis (PBC). By activating FXR, Obeticholic acid modulates bile acid synthesis and transport, reducing hepatic inflammation and fibrosis. It is indicated for patients with inadequate response or intolerance to ursodeoxycholic acid (UDCA). Obewist 10 Tablet is administered orally, with dosage tailored according to clinical response and tolerability, typically starting at 5 mg daily and titrated to 10 mg as needed. Common adverse effects include pruritus, fatigue, and abdominal discomfort, which are generally mild to moderate and manageable. Caution is advised in patients with advanced liver impairment, and periodic monitoring of liver function tests is recommended during therapy. Obewist should be used under medical supervision, considering potential drug interactions and contraindications such as severe hepatic decompensation. Its mechanism of action and clinical efficacy make Obewist 10 Tablet a valuable therapeutic option in managing cholestatic liver disorders, improving biochemical markers, and potentially delaying disease progression. Patients should adhere strictly to prescribed regimens and report any adverse symptoms promptly to their healthcare provider.